Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, No. 220, Handan Road, Yangpu District, Shanghai, 200433, China.
Institute of Modern Physics, Fudan University, No. 220, Handan Road, Yangpu District, Shanghai, 200433, China.
Sci Rep. 2020 Mar 6;10(1):4179. doi: 10.1038/s41598-020-61129-5.
This study aims to evaluate the radiation dosimetry of a new technetium-99m‒labelled small-molecule inhibitor of prostate-specific membrane antigen (HYNIC-Glu-Urea-A, Tc-HYNIC-PSMA) and its feasibility as a tumor-imaging agent in prostate cancer (PCa) patients. A total of 15 PCa patients were enrolled in this study. For the dosimetry study, 5 PCa patients received whole-body planar scans at 0.5 h, 1 h, 2 h, 4 h and 8 h after Tc-HYNIC-PSMA injection. The Dosimetry Toolkit (GE, Milwaukee) was used to process the data and segment the organs in the SPECT/CT images, which were then projected onto planar images. The organ-specific absorbed doses, total-body absorbed doses and Tc-HYNIC-PSMA effective doses of patients were calculated using OLINDA/EXM 1.1 software. Whole-body SPECT/CT images were also acquired from additional 10 prostate patients to investigate the feasibility of Tc-HYNIC-PSMA for imaging tumors by calculating the ratio of tumor-to-background tracer uptake at 2 h after 740 MBq administration. The total-body absorbed dose was 1.54E-03 ± 2.43E-04 mGy/MBq, and the effective dose was 3.72E-03 ± 4.5E-04 mSv/MBq. Compared to published studies of other similar PSMA tracers and Tc-targeted conventional tracers, the absorbed doses of Tc-HYNIC-PSMA in all organs showed that it could be used safely in the human body. In addition, Tc-HYNIC-PSMA showed high tracer uptake (with a tumor-to-background ratio of 9.42 ± 2.62) in the malignant lesions of PCa patients, making it a promising radiopharmaceutical imaging method for site-specific management of PCa.
本研究旨在评估一种新型放射性核素 99m 标记的前列腺特异性膜抗原（PSMA）小分子抑制剂（HYNIC-Glu-Urea-A，Tc-HYNIC-PSMA）的辐射剂量学，并评估其作为前列腺癌（PCa）患者肿瘤成像剂的可行性。本研究共纳入 15 例 PCa 患者。为了进行剂量学研究，5 例 PCa 患者在注射 Tc-HYNIC-PSMA 后 0.5 h、1 h、2 h、4 h 和 8 h 进行全身平面扫描。使用 Dosimetry Toolkit（GE，Milwaukee）处理数据并对 SPECT/CT 图像中的器官进行分割，然后将其投影到平面图像上。使用 OLINDA/EXM 1.1 软件计算患者的器官特异性吸收剂量、全身吸收剂量和 Tc-HYNIC-PSMA 有效剂量。还从另外 10 例前列腺患者中采集全身 SPECT/CT 图像，通过计算 740 MBq 给药后 2 h 时肿瘤与背景示踪剂摄取的比值，研究 Tc-HYNIC-PSMA 用于肿瘤成像的可行性。全身吸收剂量为 1.54E-03±2.43E-04 mGy/MBq，有效剂量为 3.72E-03±4.5E-04 mSv/MBq。与其他类似 PSMA 示踪剂和 Tc 靶向常规示踪剂的已发表研究相比，Tc-HYNIC-PSMA 在所有器官中的吸收剂量表明，它可在人体中安全使用。此外，Tc-HYNIC-PSMA 在 PCa 患者的恶性病变中显示出较高的示踪剂摄取（肿瘤与背景比值为 9.42±2.62），这使其成为一种有前途的放射性药物成像方法，可用于 PCa 的特定部位管理。
